Skin‐lightening effects of a new face care product in patients with melasma

Scherdin, U.; Bürger, Anette; Bielfeldt, S.; Filbry, Alexander; Weber, Teresa; Schölermann, A.; Wigger‐Alberti, W.; Rippke, Frank; Wilhelm, Klaus‐Peter

doi:10.1111/j.1473-2165.2008.00364.x

Cited by 15 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data provided by Scherdin et al 9 . showed that the MASI score decreased by 42.3% from baseline to the end of the study with DA after 8 weeks of treatment, comparable with the results of 2% HQ.…”

Section: Discussionsupporting

confidence: 69%

See 1 more Smart Citation

Efficacy of dioic acid compared with hydroquinone in the treatment of melasma

2009

View full text Add to dashboard Cite

Background Melasma is a common disorder of pigmentation characterized by relatively symmetric, brown or gray–brown patches on sun‐exposed facial areas. Hydroquinone, the most effective agent in melasma, is known to irritate the skin, and so new alternatives in the treatment of melasma are required. We sought to assess the clinical response of a new depigmenting agent in melasma. Methods Ninety‐six Mexican female patients with melasma were enrolled in this open, comparative, 12‐week study. The patients received 1% dioic acid cream (twice daily) or 2% hydroquinone cream (twice daily). Results There was a significant difference in the Melasma Area Severity Index (MASI) scores from baseline to the end of the study using treatment with dioic acid (baseline, 14.52 3.4; after 12 weeks of treatment, 6.05 ± 1.2; P = 0.001) and hydroquinone (baseline, 15.22 ± 2.4; after 12 weeks of treatment, 6.34 ± 1.3; P = 0.001); however, there were no significant differences between treatments (baseline, P = 0.311; after 12 weeks of treatment, P = 0.287). The side‐effects were similar with both medications; however, pruritus was more common in patients using hydroquinone. Conclusions Dioic acid is an effective and highly tolerated skin product, although further controlled, blind, multicenter studies are required to support these results.

show abstract

Section: Discussionsupporting

confidence: 69%

“…Data provided by Scherdin et al 9 showed that the MASI score decreased by 42.3% from baseline to the end of the study with DA after 8 weeks of treatment, comparable with the results of 2% HQ. This was the first study on the efficacy of DA in melasma, and demonstrated that DA is an effective and highly skin-tolerable product.…”

Section: Discussionsupporting

confidence: 66%

Efficacy of dioic acid compared with hydroquinone in the treatment of melasma

2009

View full text Add to dashboard Cite

show abstract

“…Both the vehicle‐ and the PKEK‐containing formulation improved the evenness of skin coloration and overall skin appearance compared with the baseline skin condition, but the PKEK treatment was found to be superior and significantly different to the vehicle after 12 weeks of treatment. There have been many studies examining the effect of agents on melasma and the efficacy ranged from approximately 15–70% improvement using the Melasma Area and Severity Index (MASI) or others have used the mexameter 32 . We used a different grading scale in our studies, as the subjects also had postinflammatory hyperpigmentation from acne and as such cannot directly compare with previous results.…”

Section: Discussionmentioning

confidence: 99%

“…There have been many studies examining the effect of agents on melasma and the efficacy ranged from approximately 15-70% improvement using the Melasma Area and Severity Index (MASI) or others have used the mexameter. 32 We used a different grading scale in our studies, as the subjects also had postinflammatory hyperpigmentation from acne and as such cannot directly compare with previous results. Nevertheless, clearly, the PKEK-containing formulation was highly efficacious.…”

Section: Discussionmentioning

confidence: 99%

“…9 Typical actives include retinoids, [10][11][12] niacinamide, [13][14][15][16] kojic acid, 17 arbutin and derivatives, 18,19 bisabolol, 20 soybean trypsin inhibitors, 21 azelaic acid, 22 licorice derivatives such as Glabrene and isoliquiritigenin, 23 vitamin C derivatives and other antioxidants, 24 N-acetyl glucosamine, 25,26 N-undecy-10-enoyl-L-phenylalanine, 27 hydroxyacids 28,29 and octadecenedioic acid. [30][31][32] To develop new potential ingredients for skin-lightening products, we have focused on the inflammatory pathways involved in skin pigmentation. 33 Recently, it has been shown that a peptide comprising Lys-Glu-Lys (KEK), which was further modified with a proline attached to its N-terminus (PKEK) to stabilize its structure, reduces interleukin-6 and 8, tumor necrosis factor-a and cyclo-oxygenase gene expression in ultraviolet (UV) light-stimulated keratinocytes in vitro and in vivo.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Facial skin-lightening benefits of the tetrapeptide Pro-Lys-Glu-Lys on subjects with skin types V-VI living in South Africa

Farwick

Maczkiewitz

Lersch

et al. 2011

Journal of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Melasma hyperpigmentation: An overview of current topical therapeutics

AlSalem

Alexis

2022

Dermatological Reviews

View full text Add to dashboard Cite

Background Melasma is a common disorder of hyperpigmentation that affects populations globally and can adversely affect quality of life. Topical therapies—including hydroquinone and nonhydroquinone‐containing formulations—play a central role in the management of melasma. Methods A literature review was conducted using PubMed and Google Scholar. Search keywords included a combination of the following: “melasma,” “chloasma,” and “topical treatment.” We identified and included seminal and high‐quality peer‐reviewed publications, systematic reviews, randomized controlled trials, case series, case reports, consensus statements, and expert opinions. Results Topical therapies are widely used for the treatment of melasma. Triple combination cream containing hydroquinone, fluocinolone, and tretinoin is the most studied formulation with the strongest evidence among treatment options. Numerous other prescription‐based and nonprescription topical agents, including a growing list of cosmeceuticals, have been used in the treatment of melasma, albeit in smaller studies. Conclusion A growing range of topical agents is available for the treatment of melasma. While larger, more robust studies are warranted, nonhydroquinone cosmeceuticals may be useful adjuncts or alternatives to the gold standard of triple‐combination hydroquinone cream.

show abstract

Skin‐lightening effects of a new face care product in patients with melasma

Abstract: The data demonstrate that the new face care product is effective and highly skin tolerable and clearly improves quality of life of patients with melasma.

Cited by 15 publications

References 30 publications

Efficacy of dioic acid compared with hydroquinone in the treatment of melasma

Efficacy of dioic acid compared with hydroquinone in the treatment of melasma

Facial skin-lightening benefits of the tetrapeptide Pro-Lys-Glu-Lys on subjects with skin types V-VI living in South Africa

Melasma hyperpigmentation: An overview of current topical therapeutics

Contact Info

Product

Resources

About